conversion chart semaglutide to tirzepatide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Compound Tirzepatide Dosing Chart: Complete

These combination products may have different stability profiles than standalone tirzepatide

Ro-affiliated healthcare professionals have the discretion to prescribe a medication off-label if they believe it is an appropriate course of treatment for a particular patient

Jensen is listed as the inventor

It can also make it harder to identify which medicine caused a problem

This approach is fundamentally different from surgical procedures like liposuction, which carry risks of infection, scarring, internal damage, and a recovery period that can last a week or more

Retatrutide is expected to be commercially available in 2026 or 2027